Clinical Trial Update: Pilot Open Label Use of the Hi-OXSR for the Treatment of Post COVID-19 Cognitive Dysfunction [Phase 1]

View source ↗

Summary

This Phase 1 open-label pilot study evaluating Hi-OXSR for treating post-COVID-19 cognitive dysfunction has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Post-acute Sequelae of Sars-cov-2 Infection

Drugs mentioned

• Hi-OxSR

Snippet

Sponsor: University Health Network, Toronto | Conditions: Post COVID-19 Condition | Phase 1 | Status: COMPLETED